Using MRI scans to predict early response to chemotherapy in bladder cancer
Studies whether special MRI scans can predict early response to chemotherapy before bladder surgery.
Plain-language title generated from the registry record
Registry title: Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
Key facts
- Where
- Asyut, EgyptSee the site
Where in Egypt
- Amr E. DarwishAsyut, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assiut University
- Trial code
- NCT07202845
- Record updated
- 2 October 2025
- Original description
Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable muscle-invasive bladder cancer (MIBC). However, non-response to NAC can lead to delayed surgery and unnecessary toxicity. Magnetic resonance imaging (MRI), particularly multiparametric MRI (mpMRI) with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), offers functional and quantitative biomarkers that may predict NAC response early in treatment.Read full original descriptionShow less
Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable muscle-invasive bladder cancer (MIBC). However, non-response to NAC can lead to delayed surgery and unnecessary toxicity. Magnetic resonance imaging (MRI), particularly multiparametric MRI (mpMRI) with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), offers functional and quantitative biomarkers that may predict NAC response early in treatment.
Inclusion: Patients diagnosed with cT2-T4 urothelial carcinoma of the urinary bladder, according to the TNM classification (8), who give informed, written consent on participation in the study and approve all its requirements; Planned to receive cisplatin-based NAC followed by radical cystectomy; Willing to undergo three mpMRI scans (baseline, 24h post-initial cisplatin, and post-NAC).
Exclusion: Patients who have received pelvic radiotherapy; Previous open or laparoscopic pelvic surgery; Severe renal impairment; Presence of distant metastases at diagnosis; Patients with contraindications to MRI; Ineligibility to cisplatin.